afforded trial participants stronger immunity, the company announced Monday, aiming to assuage concerns of compromised immunity among populations of countries with short vaccine supply.on The Lancet’s preprint server Monday, drawing from trial participants aged 18 to 55. Results suggested a 45-week delay between the first and second dose lent up to an 18-fold increase in antibody response, per data taken 28 days post-second dose.
"This should come as reassuring news to countries with lower supplies of the vaccine, who may be concerned about delays in providing second doses to their populations," Andrew Pollard, chief investigator and director of the Oxford Vaccine Group at the University of Oxford, said in a statement."There is an excellent response to a second dose, even after a 10 month delay from the first.
The study also examined third doses administered as booster shots; when a third shot was given at least six months after the second dose, there was a six-fold increase in antibody levels, with greater neutralizing power against concerning viral variants, including the highly transmissible Delta variant first detected in India.Further findings suggested a single dose alone resulted in waning antibody levels over the course of a year, but levels remained above baseline.
While the study's sample size wasn't large enough to pick up rare vaccine side effects, the delayed second dose and booster suggested the vaccine was well tolerated. "We demonstrate that immunity induced by the viral vectored vaccine ChAdOx1 nCoV-19 is maintained for long periods after a first dose, with greater boosting after the second dose following a longer interval between doses," the study reads."A single dose of ChAdOx1 nCoV-19, with a second dose given after a prolonged period, may therefore be an effective strategy when vaccine supplies are scarce in the short term.